Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Im-patient who wrote (3933)	3/16/1998 2:58:00 PM
From: margie	Read Replies (3) \| Respond to of 6136

Weekly IMS data for week ended March 6, showed record levels in Viracept scripts. Scripts reached a new record this week, with total Viracept scripts of 10,991, representing a 13% increase in week to week and a 30.65% market share. Viracept's new scrips achieved a record level of 3804 representing a 30.1% market share. Refills were exceptionally strong at 7187, a 17% increase week to week. Monthly data will be released March 18th. The total protease inhibitor class was up 13%. Crixivan continues to lose market share, from 38.55 to 36.6% in total scripts and to 33.5% from 35.3% in new scripts. Fortovase continues to gain market share, and Norvir is holding it's share. PW believes growth in Norvir and Fortovase scrips are being driven by their use in dual PI combination therapy. Agouron is currently trading at a P/E multiple of 23.1 x PW calendar year estimate of $1.56 per share. FYI: >>There is some interesting work being done on the Point and Figure Charting Board concerning the Biotech sector>> techstocks.com